X
Access Company Profiles

Get business overview, business operations details specific to this market, products and services, latest developments and more...

Business Email

Select Companies

 

Breast Cancer Liquid Biopsy Companies

This report lists the top Breast Cancer Liquid Biopsy companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Breast Cancer Liquid Biopsy industry.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Breast Cancer Liquid Biopsy Top Companies

  1. Roche

  2. Bio-Rad Laboratories

  3. Johnson & Johnson

  4. Biocept

  5. QIAGEN 

*Disclaimer: Top companies sorted in no particular order

Breast Cancer Liquid Biopsy Market Major Players

Breast Cancer Liquid Biopsy Market Concentration

Breast Cancer Liquid Biopsy  Market Concentration

Breast Cancer Liquid Biopsy Company List

                          • Qiagen

                          • F. Hoffmann-La Roche Ltd

                          • Bio-Rad Laboratories Inc.

                          • Janssen Diagnostics

                          • Biocept Inc.

                          • Guardant Health Inc.

                          • Myriad Genetics

                          • Adaptive Biotechnologies

                          • Epic Sciences

                          • Illumina Inc.

                          • Fluxion Biosciences Inc.

                          • Biodesix

                          • Pathway Genomics (OME Care)

                          • Exosome Diagnostics Inc.

                          • PapGene


                      Specific to Breast Cancer Liquid Biopsy Market
                      Need More Details On Market Players And Competitors?
                      Download PDF

                      Breast Cancer Liquid Biopsy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)